Evestra Onkologia in line with its strategic objectives entered into a collaboration agreement with the Medical University of Łódź. The objective of this collaboration is to take advantage of the respective competencies of both organizations in the field of biotechnology and pharmaceutical research to enhance innovation in Poland., This collaboration will also generate favorable conditions for public/private cooperation. Areas of collaboration are development of innovative medicines and therapies for use in the treatment of endocrine diseases, estrogen-dependent tumors, and in addition, training of professionals in modern biotechnology and pharmaceutical research.Read more
Evestra Onkologia Sp. z o.o is a Polish biopharmaceutical start-up company located in Lodz launched by a distinguished team with an impressive record in developing and commercializing innovative oncology and other proliferative diseases products.
The Company was launched as a wholly-owned subsidiary of Evestra, Inc., a U.S.A. biopharmaceutical company based in San Antonio, Texas. The key mission of Evestra Onkologia is to develop highly innovative oncology and antiproliferative assets such as endometriosis and fibroids in Poland, and the EU. To accomplish its core mission, the Company has and will continue to establish a variety of fruitful collaborations with leading Polish research institutions and investigators and for-profit CRO companies in Poland, to enhance development and commercialization of its innovative assets. Evestra Onkologia managing board is led by two executives of the pharmaceutical as well as life science industry with extensive in drug development and managing companies with multinational divisions. Dr. Ze’ev Shaked, Ph.D. has multi-disciplinary track record in oncology including development and commercialization of novel antimetabolites to treat hematological cancers, biologics such as cytotoxic monoclonal antibodies and cytokines to treat a wide range of solid tumor indications. Both board members hold numerous patents and have managed R&D departments and projects for many years. Dr Maciej Wierzbicki, Ph.D. has experienced the development of early stage ventures in the field of life science technology, including the acquisition of financing and project management